Basel, 23 November 2018 - Roche (SIX: RO, ROG; OTCQX: RHHBY) is launching its Viewics analytics platform for labs and hospitals with two new globally, standardized application solutions: LabOPS and Dx Optimization. LabOPS helps lab and hospital decision-makers access their own data more effectively and make fact-based decisions to reduce waste and improve the decisions made around the operational and financial processes of their institutions. LabOPS is available in five languages: English, French, German, Spanish and Brazilian Portuguese. The data generated by Dx Optimization helps improve decisions made around clinical effectiveness in institutions; it is available in English for US and Canada.
“Digitalisation of healthcare is enabling the easy flow of data between diagnostic instruments and devices, and the professionals who operate them, noted Christian Hebich, Global Head of Solution Integration & Services.” “Viewics – and all our software applications at Roche – strengthen not only our integrated core lab offering they also generate actionable insights that increase productivity, value for institutions and improve the delivery of quality patient care.”
An expanding suite of software services and solutions
Viewics complements the suite of Roche’s insight-driven services and solutions for labs and hospitals to generate actionable insights that reduce complexity and help improve delivery of care. The Viewics platform integrates data efficiently from a broad array of IT systems in laboratory and other healthcare settings. The applications are the first to launch since Viewics, the company, was acquired by Roche in 2017.
In another key example: cobas® infinity central lab solution reached a key milestone with over 1200 installations in over 45 countries till date. This is Roche’s browser-based laboratory software solution that drives integration across pre-analytics, analytics and post-analytics by automating the entire sample flow from ordering to archiving. The advanced workflow engine drives intelligent sample processing and auto-validation for efficient result management.
This year Roche also launched Roche Healthcare Consulting, a worldwide network of 250+ consultants. These experts work with lab and hospital leaders to help them turn data analytics into tangible actions and insights that can improve operational and financial effectiveness and organisational sustainability as well as manage the challenges of digital transformation. For more information, please visit diagnostics.roche.com
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.